Anemia Therapy in ESRD: Time to Move On

[摘要] The discovery of erythropoietin and then its provision as a drug were rightly hailed as landmarks in nephrology. However, in efforts to define its use, four large randomized trials over the last 12 years have found few of the hypothesized benefits and some unexpected harm. Physicians are now told to give every patient for whom an erythropoiesis-stimulating agent (ESA) is prescribed a five-page warning that begins with this question and answer “What is the most important information I should know about Epogen? Using Epogen can lead to death or other serious side effects.” What went wrong?

[学科分类] 泌尿医学

[关键词] Bone marrow necrosis;Sickle cell disease;Hyperhemolysis syndrome